🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. cadonilimab combined +paclitaxel (albumin-bound)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. cadonilizumab combined with neoadjuvant radiochemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 other active

    1 trial

  3. cemiplimab

    Regeneron UK Limited

    Cutaneous Basal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. cemiplimab

    Regeneron UK Limited

    Advanced Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  5. chidamide + camrelizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  6. cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  7. compound diclofenac sodium

    The First People's Hospital of Lianyungang

    Acute Abdominal Pain

    phase 2 small molecule active

    1 trial

  8. dabrafenib

    GlaxoSmithKline

    Solid Tumours

    phase 2 small molecule completed

    1 trial

  9. docetaxel+CDDP

    Solid Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial

  10. docetaxel, cisplatin, fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Head and Neck Carcinoma

    phase 2 small molecule completed

    1 trial

  11. electroacupuncture group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Urinary Stress Incontinence

    phase 2 other completed

    1 trial

  12. empowerment theory-based small group discussion

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infection

    phase 2 other completed

    1 trial

  13. etrasimod

    MAIA Biotechnology

    Pouchitis

    phase 2 small molecule active

    1 trial

  14. experimental group x-MAP

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer (mCRC)

    phase 2 other active

    1 trial

  15. experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo

    Universal Integrated

    Anovulatory Infertility

    phase 2 small molecule active

    1 trial

  16. gemcitabine and cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  17. genexolPM + cisplatin

    Solid Biosciences

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  18. idecabtagene vicleucel

    Celgene Europe Limited

    Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)

    phase 2 small molecule active

    1 trial

  19. implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).

    Lxo Ireland Designated Activity Company

    Cleft Lip and Palate

    phase 2 other active

    1 trial

  20. interleukin-4 PE38KDEL cytotoxin

    NEUROCRINE BIOSCIENCES INC

    Brain and Central Nervous System Tumors

    phase 2 mab completed

    1 trial

  21. intravenous infusion (IV) of Adebrelimab (ADE)

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  22. linrodostat mesylate; IDO1 inhibitor, linrodostat mesylate; IDO1 inhibitor, Ipilimumab, Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion., linrodostat mesylate; IDO1 inhibitor, Ipilimumab

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  23. long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations

    BEONE MEDICINES AUS PTY LTD

    Colorectal Neoplasms

    phase 2 other active

    1 trial

  24. low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources